![K. Hirth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
K. Hirth
Directeur/Membre du Conseil chez
ALIGOS THERAPEUTICS, INC.
Fortune : 13 566 $ au 31/05/2026
Profil
K.
Peter Hirth was the founder of Plexxikon, Inc., founded in 2001, where the title held was Chief Executive Officer & Director in 2013.
Current jobs include Chairman at IO Biotech ApS; Director at KineMed, Inc. since 2013; Director at Iconic Therapeutics, Inc. since 2015; Director at Afferent Pharmaceuticals, Inc. since 2014; Director at Enterome SA since 2023; Director at Escient Pharmaceuticals, Inc. since 2019; Independent Director at Aligos Therapeutics, Inc. since 2018; Director at TRex Bio Ltd. since 2019; and Venture Partner at Wellington Partners GmbH since 2022.
Former jobs include Independent Chairman at IO Biotech, Inc. from 2016 to 2026; Director at Alios BioPharma, Inc.; Director at Kolltan Pharmaceuticals, Inc.; Independent Director at Vaxcyte, Inc. from 2016 to 2025; Director at Aria Biosystems Corp.; President at Sugen, Inc.; Vice President-Research at Roche Diagnostics GmbH; and Vice President-Research at Max-Planck-Institute for Molecular Genetics.
Education includes graduate and doctorate degrees from Ruprecht-Karls-Universität Heidelberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 2 380 ( 0,04 % ) | 13 566 $ | 31/05/2026 | |
IO BIOTECH, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de K. Hirth
| Sociétés | Poste | Début |
|---|---|---|
| KINEMED INC | Directeur/Membre du Conseil | 30/08/2013 |
| ALIGOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2018 |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunoconjugate proteins intended to translate scientific insight into breakthrough medicines for serious diseases | Directeur/Membre du Conseil | 01/05/2015 |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Develops immunomodulatory drugs for treatment of cancer | Directeur/Membre du Conseil | 18/12/2023 |
TRex Bio Ltd.
 TRex Bio Ltd. BiotechnologyHealth Technology Provides biotechnology research and development services | Directeur/Membre du Conseil | 24/06/2019 |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Directeur/Membre du Conseil | 24/09/2019 |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Président | - |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Directeur/Membre du Conseil | 03/12/2014 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Germany, Europe and beyond. The firm focuses on life sciences companies. It provides financing for early and growth stage capital requirements with an investments size of EUR 2 - 20 million. It also acts as a lead and co-lead investor. | Private Equity Investor | 01/01/2022 |
Anciens postes connus de K. Hirth
| Sociétés | Poste | Fin |
|---|---|---|
| ░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Formation de K. Hirth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
19
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 19 |
|---|---|
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs and related pharmaceutical products | Health Technology |
KineMed, Inc.
 KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes biomarker platform technology | Commercial Services |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunoconjugate proteins intended to translate scientific insight into breakthrough medicines for serious diseases | Health Technology |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Germany, Europe and beyond. The firm focuses on life sciences companies. It provides financing for early and growth stage capital requirements with an investments size of EUR 2 - 20 million. It also acts as a lead and co-lead investor. | Finance |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops innovative medicines, treatments and diagnostics | Commercial Services |
ForteBio, Inc.
 ForteBio, Inc. Medical SpecialtiesHealth Technology Develops, manufactures, and markets biomolecular analysis products | Health Technology |
Ruprecht-Karls-Universität Heidelberg
 Ruprecht-Karls-Universität Heidelberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max-Planck-Institute for Molecular Genetics
 Max-Planck-Institute for Molecular Genetics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Develops immunomodulatory drugs for treatment of cancer | Health Technology |
Vaxcyte, Inc.
 Vaxcyte, Inc. BiotechnologyHealth Technology Develops vaccines for infectious diseases | Health Technology |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Health Technology |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Health Technology |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
TRex Bio Ltd.
TRex Bio Ltd. BiotechnologyHealth Technology Provides biotechnology research and development services | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
